meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced RCC (mRCC) - 2nd line (L2)
2
sarcomas
thyroid cancer
urothelial cancer (UC) - bladder cancer (BC)
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone
atezolizumab plus SoC
avelumab based treatment
avelumab alone
durvalumab based treatment
durvalumab alone
nivolumab based treatment
nivolumab alone
pembrolizumab based treatment
pembrolizumab alone
pembrolizumab plus SoC
Immune checkpoint association
durvalumab plus tremelimumab
versus all
vs chemotherapy
vs platinum-based chemotherapy
vs platinum derivate
vs platinum association
vs gemcitabine plus platin
vs Standard of Care (SoC)
vs placebo plus SoC
vs non active control
vs BSC
vs no additional treatment
vs placebo
All patients
Age < 65y (younger)
Age > 65y
Age > 75y (older)
Asian type
ECOG ⩾ 1
ECOG 0
ECOG 1
Gender, female
Gender, male
Hemoglobin concentration < 10g/dl
hemoglobin concentration > 10g/dl
metastasis (liver )
metastasis (lymph node )
metastasis (visceral)
PD-L1 < 1%
PD-L1 < 10%
PD-L1 < 5%
PD-L1 > 1%
PD-L1 > 10%
PD-L1 > 5%
PDL1 (TC0 and IC0 : <1% of TC and IC)
PDL1 (TC2/3 or IC2/3 : ≥5% of TC or IC)
PDL1 < 25%
PDL1 >25%
smoker (current or former)
smoker (Current)
smoker (Former)
smoker (never)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
CRR
DCR
deaths (OS)
deaths (OS) (extension)
DMFS
DOR
DOR (extension)
events or deaths (EFS)
objective responses (ORR)
objective responses (ORR) (extension)
PFS (extension)
progression or deaths (PFS)
RFS/DFS
AE (any grade)
AE (grade 3-4)
AE (grade 3-5)
AE leading to death (grade 5)
AE leading to treatment discontinuation (any grade)
AE leading to treatment discontinuation (grade 3-4)
SAE (any grade)
STRAE (any grade)
TRAE (any grade)
TRAE (grade 3-4)
TRAE leading to death (grade 5)
TRAE leading to discontinuation (any grade)
TRAE leading to discontinuation (grade 3-4)
Abdominal pain TRAE (grade 3-4)
Acute kidney injury TRAE (grade 3-4)
Adrenal insufficiency TRAE (grade 3-4)
Alopecia TRAE (grade 3-4)
Anaemia TRAE (grade 3-4)
Arthralgia TRAE (grade 3-4)
Arthritis TRAE (grade 3-4)
Asthenia TRAE (grade 3-4)
Blood creatinine increased TRAE (grade 3-4)
Chills TRAE (grade 3-4)
Colitis TRAE (grade 3-4)
Constipation TRAE (grade 3-4)
Decreased appetite TRAE (grade 3-4)
Dermatitis acneiform TRAE (grade 3-4)
Diabetes TRAE (grade 3-4)
Diarrhoea TRAE (grade 3-4)
Dry skin TRAE (grade 3-4)
Dyspnoea TRAE (grade 3-4)
Eczema TRAE (grade 3-4)
Endocrine disorders TRAE (grade 3-4)
Erythema TRAE (grade 3-4)
Fatigue TRAE (grade 3-4)
Febrile neutropenia TRAE (grade 3-4)
Gastritis TRAE (grade 3-4)
Gastrointestinal disorders TRAE (grade 3-4)
Guillain-Barré syndrome TRAE (grade 3-4)
Hepatitis TRAE (grade 3-4)
Hypersensitivity TRAE (grade 3-4)
Hyperthyroidism TRAE (grade 3-4)
Hypophysitis TRAE (grade 3-4)
Hypothyroidism TRAE (grade 3-4)
Increase AST TRAE (grade 3-4)
Increased ALT TRAE (grade 3-4)
Increased lipase level TRAE (grade 3-4)
Infusion-related reactions TRAE (grade 3-4)
Leucopenia TRAE (grade 3-4)
Maculopapular rash TRAE (grade 3-4)
Myocarditis TRAE (grade 3-4)
Myositis TRAE (grade 3-4)
Nausea TRAE (grade 3-4)
Nephritis TRAE (grade 3-4)
Neutropenia TRAE (grade 3-4)
Pancreatitis TRAE (grade 3-4)
Pancytopenia TRAE (grade 3-4)
Peripheral neuropathy TRAE (grade 3-4)
Pneumonitis TRAE (grade 3-4)
Pruritic rash TRAE (grade 3-4)
Pruritus TRAE (grade 3-4)
Pyrexia TRAE (grade 3-4)
Rash TRAE (grade 3-4)
Renal and urinary disorders TRAE (grade 3-4)
Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4)
Sarcoidosis TRAE (grade 3-4)
Sepsis TRAE (grade 3-4)
Severe skin reaction TRAE (grade 3-4)
Stevens-Johnson syndrome TRAE (grade 3-4)
Stomatitis TRAE (grade 3-4)
Thrombocytopenia TRAE (grade 3-4)
Thyroiditis TRAE (grade 3-4)
Urticaria TRAE (grade 3-4)
Uveitis TRAE (grade 3-4)
Vitiligo TRAE (grade 3-4)
Vomiting TRAE (grade 3-4)
hepatitis (Autoimmune) AE (grade 3-4)
Abdominal pain AE (grade 3-4)
Acute kidney injury AE (grade 3-4)
Agranulocytosis (AE grade 3-4)
Alopecia AE (grade 3-4)
Anaemia AE (grade 3-4)
Arthralgia AE (grade 3-4)
Asthenia AE (grade 3-4)
Back pain AE (grade 3-4)
Blood and lymphatic system disorders AE (grade 3-4)
Blood creatinine increased AE (grade 3-4)
Cardiac disorders AE (grade 3-4)
Constipation AE (grade 3-4)
Cough AE (grade 3-4)
Decreased appetite AE (grade 3-4)
Diarrhoea AE (grade 3-4)
Dizziness AE (grade 3-4)
Dry skin AE (grade 3-4)
Dysgeusia AE (grade 3-4)
Dyspnoea AE (grade 3-4)
Endocrine disorders AE (grade 3-4)
Eye disorders AE (grade 3-4)
Fatigue AE (grade 3-4)
Febrile neutropenia AE (grade 3-4)
Gastrointestinal disorders AE (grade 3-4)
General disorders and administration site conditions AE (grade 3-4)
Headache AE (grade 3-4)
Hypertension AE (grade 3-4)
Hypothyroidism AE (grade 3-4)
Increase AST AE (grade 3-4)
Increased ALT AE (grade 3-4)
Infections and infestations AE (grade 3-4)
Infusion-related reaction AE (grade 3-4)
Injury, poisoning and procedure AE (grade 3-4)
Investigations AE (grade 3-4)
Leucopenia AE (grade 3-4)
Metabolism and nutrition disorders AE (grade 3-4)
Mucosal inflammation AE (grade 3-4)
Musculoskeletal and connective tissue disorders AE (grade 3-4)
Myalgia AE (grade 3-4)
Nausea AE (grade 3-4)
Nervous system disorders AE (grade 3-4)
Neutropenia AE (grade 3-4)
Peripheral neuropathy AE (grade 3-4)
Peripheral oedema AE (grade 3-4)
Pruritus AE (grade 3-4)
Pyrexia AE (grade 3-4)
Rash AE (grade 3-4)
Renal and urinary disorders AE (grade 3-4)
Respiratory, thoracic and mediastinal disorders AE (grade 3-4)
Skin and subcutaneous tissue disorders AE (grade 3-4)
Stomatitis AE (grade 3-4)
Thrombocytopenia AE (grade 3-4)
Vascular disorders AE (grade 3-4)
Vomiting AE (grade 3-4)
Weight decreased AE (grade 3-4)
CRR
mUC - L1 - all population
metastatic/advanced UC (mUC) - 1st Line (L1)
mUC - L1 - all population
versus gemcitabine plus platin
atezolizumab alone vs. gemcitabine plus platin
1
-
durvalumab alone vs. gemcitabine plus platin
1
-
durvalumab plus tremelimumab vs. gemcitabine plus platin
1
-
pembrolizumab plus SoC vs. gemcitabine plus platin
1
-
versus placebo plus SoC
atezolizumab plus SoC vs. placebo plus SoC
1
certainty unassessable
+96%
versus Standard of Care (SoC)
pembrolizumab alone vs. Standard of Care (SoC)
1
-
mUC - L1 - PDL1 positive
metastatic/advanced UC (mUC) - 1st Line (L1)
mUC - L1 - PDL1 positive
versus gemcitabine plus platin
durvalumab alone vs. gemcitabine plus platin
1
-
durvalumab plus tremelimumab vs. gemcitabine plus platin
1
-
mUC - L2 - all population
metastatic/advanced UC (mUC) - 2nd Line (L2)
mUC - L2 - all population
versus Standard of Care (SoC)
atezolizumab alone vs. Standard of Care (SoC)
1
-
pembrolizumab alone vs. Standard of Care (SoC)
1
-
mUC - L2 - PDL1 positive
metastatic/advanced UC (mUC) - 2nd Line (L2)
mUC - L2 - PDL1 positive
versus Standard of Care (SoC)
atezolizumab alone vs. Standard of Care (SoC)
2
-
pembrolizumab alone vs. Standard of Care (SoC)
1
-
mUC - M - all population
metastatic/advanced UC (mUC) - maintenance (M)
mUC - M - all population
versus BSC
avelumab alone vs. BSC
1
-
mUC - M - PDL1 positive
metastatic/advanced UC (mUC) - maintenance (M)
mUC - M - PDL1 positive
versus BSC
avelumab alone vs. BSC
1
-
MIBC - NA - all population
muscular invasive bladder cancer (MIBC)
MIBC - (neo)adjuvant (NA)
MIBC - NA - all population
versus no additional treatment
atezolizumab alone vs. no additional treatment
1
-
versus placebo
nivolumab alone vs. placebo
1
-
MIBC - NA - PDL1 positive
muscular invasive bladder cancer (MIBC)
MIBC - (neo)adjuvant (NA)
MIBC - NA - PDL1 positive
versus placebo
nivolumab alone vs. placebo
1
-
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open